Frontier Capital Management Co. LLC Boosts Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Frontier Capital Management Co. LLC raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 17.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,899,761 shares of the company's stock after purchasing an additional 435,350 shares during the quarter. Frontier Capital Management Co. LLC owned 0.59% of Elanco Animal Health worth $35,116,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its holdings in Elanco Animal Health by 28.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock valued at $124,000 after buying an additional 2,264 shares in the last quarter. DDD Partners LLC bought a new stake in Elanco Animal Health during the 4th quarter valued at about $5,974,000. Dimensional Fund Advisors LP lifted its holdings in Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after buying an additional 1,074,274 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after purchasing an additional 209,734 shares during the period. Finally, Franklin Resources Inc. increased its position in Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock valued at $5,349,000 after purchasing an additional 45,795 shares during the period. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

Shares of ELAN traded down $0.26 during trading hours on Friday, hitting $12.02. The stock had a trading volume of 8,518,434 shares, compared to its average volume of 4,986,928. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a 50-day moving average price of $9.89 and a 200 day moving average price of $11.42. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The firm has a market capitalization of $5.97 billion, a price-to-earnings ratio of 30.05, a PEG ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm earned $0.34 EPS. The firm's revenue was down 1.0% compared to the same quarter last year. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.89% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on ELAN shares. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Barclays cut their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Piper Sandler cut their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $15.00.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.